Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy ® (semaglutide), which includes ...

As part of its collaboration with Novo Nordisk announced ... growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

A focused research and development strategy ... for future litigation risk at roughly 2% of non-GAAP net income (high relative to the rest of the branded drug industry). Novo Nordisk has a broad ...

Novo Nordisk and GSK plc announced licensing deals ... Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Donald Trump’s threat to impose a 50 per cent tariff on all exports from the EU would deliver a hammer blow to key ...

Novo Nordisk is itself investing in such technology, and is aiming to introduce more connected devices, such as digital insulin pens, in the future ... development strategy for key brands ...